drugset / Trial / NCT01790438

A Study to Compare a New Long-Acting Insulin (LY2605541) and Human Insulin NPH in Participants With Type 2 Diabetes

NCT01790438

Phase 3 Completed 641 enrolled Eli Lilly and Company
RandomizedParallel-groupOpen-labelTreatment

Summary

The purpose of this study is to compare LY2605541 and human insulin isophane suspension (NPH) using the following measures for participants treated for up to 26 weeks: * Change in participants' overall blood sugar control * The rate of night time low blood sugar episodes * The number of participants that reach blood sugar targets without low night time blood sugar episodes * The total number of low blood sugar episodes reported

Timeline

Start
2013-03
Primary completion
2014-05
Completion
2014-05

Drugs

EvaluationDrugModalityDoseRoute
Comparator Human Insulin NPH Protein / enzyme biologic 10 iu Subcutaneous
Subject Insulin Peglispro Protein / enzyme biologic 10 iu Subcutaneous